Novo Nordisk on Friday launched its widely used diabetes and weight-management drug Ozempic in India, with prices starting at ₹8,800 for a four-week pack.
Ozempic, a once-weekly injectable formulation of semaglutide, has been approved in India for adults with uncontrolled type 2 diabetes when used along with diet and exercise.
Also Read | IndiGo under scrutiny: DGCA terminates four FOIs, summons CEO and COO
Three dose strengths, single use prefilled pens
The company said the drug will be available in three dose strengths, 0.25 mg, 0.5 mg and 1 mg which will be delivered through single-use pre-filled pens fitted with Novofine needles for painless subcutaneous injections. Each pen contains four weekly doses. The 0.25 mg starter dose is priced at ₹8,800, followed by ₹10,170 for 0.5 mg and ₹11,175 for 1 mg, according to Novo Nordisk.
As per a Zee News report, Vikrant Shrotriya, Managing Director of Novo Nordisk India, said the launch marks “a major milestone” for the company. “Ozempic offers Indian doctors an effective treatment choice supported by global clinical evidence and a strong supply chain,” he said, adding that the therapy aims to improve glycaemic control, support weight management, and protect long-term heart and kidney health through an easy-to-use weekly pen.
Also Read | Luthra brothers being extradited to India after arrest in Thailand: What's the process?
Ozempic received approval from the US Food and Drug Administration (FDA) in 2017 for type 2 diabetes and has since gained global traction for its appetite-suppressing effects, often leading to significant weight loss in patients. Novo Nordisk said the drug is part of the GLP-1 receptor agonist class, which helps lower HbA1c levels, regulate appetite, reduce food intake and lower cardiovascular and kidney risks associated with diabetes.
